Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Low utilisation of diagnostic microbiology for community acquired pneumonia in regional Victoria

CAMERON J. JEREMIAH*, LIAM M. HANNAN†§, ROB BAIRD||, GRANT PHELPS¶ and BRETT KNIGHT**

Division of Medicine, The Northern Hospital, Melbourne, †Department of Infectious Diseases, St Vincent’s Hospital, Melbourne, ‡Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, §Institute for Breathing and Sleep, Austin Hospital, Melbourne, Victoria, ||Department of Microbiology, Royal Darwin Hospital, Darwin, Northern Territory, ¶Consultant Physician and Medical Administrator, Ballarat, and **Ballarat Health Services, Ballarat, Victoria, Australia

Summary
Aims: Diagnostic microbiology for community acquired pneumonia (CAP) provides useful information for patient management, infection control and epidemiological surveillance. Newer techniques enhance that information and the time interval for obtaining results. An audit of diagnostic microbiology utilisation, microbiological aetiology, and influence of results on prescribing practices in CAP in a regional Australian hospital setting was performed.

Methods: Clinical, microbiological and outcome data were collected by medical record review of patients discharged from Ballarat Hospital with a diagnosis of CAP over a 12 month period.

Results: Of 184 identified CAP episodes, 47 (25.5%) had no diagnostic microbiology performed. Respiratory virus polymerase chain reaction (PCR) was rarely performed (2.7% of all episodes). Acute serology was frequently requested, however paired acute and convalescent serology was infrequently performed (5/75 testing episodes; 6.7%). CAP severity was not correlated with microbiological investigation intensity. The most common pathogens identified were Streptococcus pneumoniae and Mycoplasma pneumoniae (5.4% and 2.2%, respectively). Diagnostic testing appeared to rarely influence antimicrobial prescribing.

Conclusions: In this setting, diagnostic microbiological tests such as respiratory virus PCR and urinary antigen tests are under-utilised. In contrast, sputum and serological investigations are commonly requested, however rarely influence practice. Interventions to facilitate efficient usage of diagnostic microbiology are required.

Key words: Community acquired pneumonia, investigation, microbiology.

Received 1 May, revised 17 September, accepted 18 September 2012

INTRODUCTION
Community acquired pneumonia (CAP) is a common presentation to emergency departments and a frequent reason for hospital admission. Of admitted patients, 30 day mortality in Australian hospitals is 5.7%, but varies with severity.1,2 Local and international groups have published guidelines for the management of CAP, including the use of antibiotics and microbiological investigations.3–5 The underlying microbial cause of CAP in various populations has been well described, however more limited data are available for CAP in Australian rural settings.1 Ballarat Hospital is the largest hospital in the Grampians region of Victoria, and services an estimated 224 000 people spread over 48 000 square kilometers. It provides 221 acute inpatient beds and services the regional centre of Ballarat (population 96 000). This 12 month retrospective audit of CAP admissions to Ballarat Hospital was conducted to assess frequency of investigation, microbiological aetiology and corresponding clinical outcomes.

MATERIALS AND METHODS
Setting and patient selection
Patient records from all patients admitted to Ballarat Hospital with a discharge diagnosis of CAP between 1 October 2007 and 30 September 2008 were retrieved and reviewed. Patients meeting all the following criteria were included: discharge diagnosis of CAP, clinical syndrome compatible with CAP, consolidation on chest radiography (as reported by a radiologist), and age ≥18 years. Patients with suspected aspiration pneumonia, hospital acquired pneumonia, significant immunosuppression (active treatment for malignancy, prior organ transplantation, HIV, use of >10 mg prednisolone per day in the previous month, or equivalent immunosuppressive agent), or transfer from another healthcare facility were excluded. Parameters allowing calculation of the pneumonia severity index (PSI), discharge data, length of stay and antibiotic treatment regimens were collected.4 Where available, results of blood cultures, sputum microscopy and culture, urinary antigens for Strep-tococcus pneumoniae and Legionella pneumonia (PUAT and LUAT, respectively), nose and/or throat swabs for respiratory viruses and acute and convalescent serology for respiratory pathogens were recorded from the hospital pathology system. Ethics approval was not required for this retrospective audit.

Microbiological investigations
Microbiological investigations were performed as per treating clinician discretion, with reference to recommendations in national guidelines.5 Conventional techniques were used for aerobic and anaerobic blood cultures, sputum microscopy and culture. A significant result on sputum microscopy and culture was only recorded if all of the following criteria were met: sample was collected within 24 h of admission, there was a predominance of neutrophils on microscopy, and both microscopy and culture were concordant. Nose and/or throat swabs for respiratory viruses (influenza A and B, parainfluenzae 1–3, picornavirus, respiratory syncytial virus and adenovirus) were processed for multiplex polymerase chain reaction (PCR) as previously described.6 Serology for Mycoplasma pneumoniae was by particle agglutination (Serodia; Fujirebio, Japan), L. pneumophila by immunofluorescence (L. pneumophila serogroup 1–6 IgG; QML Pathology), influenza A and B by complement fixation (Victorian Infectious Diseases Reference Laboratory; VIDRL), Campylobacter fetus phase I and II by complement fixation (VIDRL) and Chlamydia group serology by ELISA (SeroELISA; Savvy Diagnostics, Israel) with speciation by immunofluorescence if required. PUAT (BinaxNOW pneumococcal urinary antigen
C. burnetii phase 2 antibodies (IgG or IgM); or detectable respiratory virus by PCR in nose or throat swabs.

In 24 episodes a probable causative pathogen was identified. In 23 of these 24 cases, results were available within a clinically useful timeframe (prior to discharge, death or completion of prescribed antibiotic course), however in one patient results were only available post-mortem (blood culture growing meticillin resistant Staphylococcus aureus). In six of these 24 episodes (26.1%) where a probable causative pathogen was identified, the result appeared to influence antibiotic prescribing, while in the remaining cases, broad-spectrum or combination antimicrobials were continued.

**DISCUSSION**

In the largest study of microbial aetiology of CAP in Australia, a likely pathogen was identified in 45.6% of 885 episodes. Studies of microbial aetiology in CAP in various settings have identified a pathogen in 7–80% of patients. Much of this diagnostic variation is accounted for by intensity of investigation and study setting. Thus the 13.0% pathogen identification rate of our study is not unexpected given invasive detection kit and LUAT (BinaxNOW Legionella urinary antigen ELA kit) were performed on un-concentrated urine specimens as per the manufacturer’s instructions (Alere, USA).

**Outcome measures**

The proportion of patients having microbiological investigation and the yield (proportions of tests performed returning a positive result) of various tests were expressed as percentages. Association between PSI and the number of tests performed and likely yield of causative pathogen was assessed using Mann–Whitney U test.

Where a pathogen was identified, this was interpreted as the probable causative pathogen if any of the following criteria were met: culture of an organism known to cause CAP from blood cultures; any positive urinary antigen; compatible sputum culture and microscopy in a good quality sputum specimen (defined above); an initial antibody titre $\geq$160 for M. pneumoniae or >4-fold rise between acute and convalescent phase (M. pneumoniae, L. pneumophila, Chlamydia species or influenza A/B); elevation of C. burnetii phase 2 antibodies (IgG or IgM); or detectable respiratory virus by PCR in nose or throat swabs.

Microbiological investigations were determined to have influenced antibiotic prescribing where antibiotic spectrum changed to target the identified pathogen.

**Statistical analysis**

Data collection and analysis was performed using Microsoft Excel (Microsoft, USA) and Stata version 9 (StataCorp, USA).

**RESULTS**

Over the 12 month period, 422 episodes of CAP were identified in 396 patients. Patient records were reviewed in 391 patients, with 184 episodes of CAP meeting the inclusion criteria. The main reasons for exclusion were absence of radiological changes, suspected aspiration or hospital acquired pneumonia, immunosuppression or malignancy. In all included patients, complete clinical data allowing determination of PSI, length of stay and in-hospital mortality was available. The cohort had a median age of 72 years with a 7.1% in-hospital mortality rate (12.5% for PSI class 4–5 CAP), 14.1% intensive care unit (ICU)/high dependency unit (HDU) admission rate and 5 day median length of stay. PSI distribution across classes 1–5 was 11.4%, 16.3%, 15.8%, 34.8% and 21.7%, respectively.

No microbiological investigation was performed in 47 of 184 (25.5%) patient episodes, with a median of one investigation performed per episode [interquartile range (IQR) 0, 3]. Investigation intensity was the same in mild to moderate (PSI 1–3) and moderate to severe (PSI 4–5) CAP [median number of investigations per CAP episode IQR 0, 3] and 1 (IQR 1, 2) respectively; Mann-Whitney test, $z = 0.66, p = 0.51$).

Blood cultures were taken in nearly 60% of episodes, and were the most common microbiological investigation, whereas assessment for respiratory viruses was rarely undertaken (2.7% of episodes; Fig. 1). Further, use of respiratory virus PCR, PUAT and LUAT was particularly low in PSI 4–5 CAP (2.9%, 15.4% and 20.2%, respectively).

Of all 184 episodes, at least one probable causative pathogen was identified in 24 episodes (13.0%). The most common pathogens identified were S. pneumoniae and M. pneumoniae (Table 1). One patient had S. pneumoniae detected by both sputum analysis and PUAT, and another patient had simultaneous detection of Haemophilus influenzae and Moraxella catarrhalis in sputum.

**Yield of tests**

Overall, 24 of 137 (17.5%) episodes where at least one microbiological investigation was performed had a probable causative pathogen identified. Yields (and 95% confidence intervals) for the more commonly performed tests were as follows: blood cultures 3.6% (95% CI 1.1–9.3%), LUAT 0% (95% CI 0–8.7%), sputum m/c 13.7% (95% CI 7.4–23.6%), PUAT 5.7% (95% CI 0.6–19.6%) and Mycoplasma serology 9.5% (95% CI 3.2–22.6%). Respiratory virus PCR appeared to have the highest yield of all microbiological investigations (20%; 95% CI 2–64%), however low utilisation compromises interpretation. Low test utilisation limited significance of yield calculations for other investigations.

The yield of the microbiological investigations according to PSI was not associated with PSI severity (PSI 1–3 yield 6.8% per test compared to PSI 4–5 yield 8.4%; Mann–Whitney test, $z = -0.19, p = 0.85$). The number of episodes in which a probable causative pathogen was identified was insufficient to make a comparison between pathogen and mortality or length of stay.

Influence of investigation results on antimicrobial prescribing

In 24 episodes a probable causative pathogen was identified. In 23 of these episodes, results were available within a clinically useful timeframe (prior to discharge, death or completion of prescribed antibiotic course), however in one patient results were only available post-mortem (blood culture growing meticillin resistant Staphylococcus aureus). In six of these 24 episodes (26.1%) where a probable causative pathogen was identified, the result appeared to influence antibiotic prescribing, while in the remaining cases, broad-spectrum or combination antimicrobials were continued.
Diagnostic methods were not employed and that the study was a retrospective audit of clinical practice.

*Streptococcus pneumoniae* (5.4%) was the most commonly identified pathogen, and reflects the findings of similar studies where *S. pneumoniae* has been less frequently identified as a pathogen in CAP compared with historical studies.1,2 *Mycoplasma pneumoniae* was the next most frequent pathogen (2.2%), although it is well known that *M. pneumoniae* rates vary significantly with epidemics occurring approximately every 4 years.3 Three episodes of *S. aureus* CAP (1.6%) and one episode of *Escherichia coli* CAP (0.5%) were identified, and although previously reported, these pathogens are unusual causes of CAP and may reflect inaccuracies in case ascertainment.4 Overall, relative rates of various pathogens were similar to those in other temperate Australian and international studies.1,3,4,13,16

Diagnostic microbiological investigation in CAP is controversial.5,17 Blood and sputum cultures (where available) are recommended when certain clinical criteria are met (e.g., patients in the ICU, moderate to severe CAP, cavitating lesions, failure of outpatient therapy or presence of a pleural effusion).3,4 Serological studies for *M. pneumoniae*, *Chlamydophila* species, *Legionella* species, and influenza are more useful for epidemiological surveillance, whereas investigations such as respiratory virus PCR and urinary antigen tests provide more timely results which may directly impact patient care.3,4,18,19 In this study where 56.5% had at least moderate to severe CAP (PSI class 4–5), the median number of microbiological investigations performed per patient episode was low at one per episode.

In moderate to severe CAP (104 episodes), 64.4% had blood cultures collected and 39.4% had sputum collected, which is comparable to prior studies.15 Lack of fever or prior antibiotic administration may explain the low blood culture collection rate, however such data were not collected. Blood cultures have limited sensitivity in CAP, but excellent specificity once contaminants are excluded.3 Their greater utility is in the ability to provide prognostic information, facilitate monitoring of antimicrobial susceptibility profiles of invasive pathogens, allow detection of unexpected bacteremia (e.g., infective endocarditis) or important pathogens (e.g., *S. aureus*, *Pseudomonas aeruginosa*) and provide a clue for identifying patients with underlying predisposing conditions (e.g., pneumococcal bacteremia and HIV or hyposplenism). In this study, blood culture yield was low at 3.6%, however positive cultures appeared to provide prognostic information (2/4 bacteremic patients did not survive to discharge) and dictated a change in antimicrobial prescribing (1 patient with methicillin resistant *S. aureus* and 1 patient with methicillin sensitive *S. aureus* requiring targeted therapy).3 Thus blood culture collection is recommended for all hospitalised patients with moderate to severe CAP, irrespective of patient temperature.

Sputum microscopy and culture when available (up to 40% of patients are unable to produce an appropriate sputum sample) has both limited sensitivity and specificity.3 In this study, sputum was collected in 39.7% of CAP episodes, with a positive yield of 13.7%. This is lower than previously reported (19.7%) and possibly related to stricter sputum analysis criteria.1 Sputum identified a likely pathogen in 10 episodes, and appeared to influence antimicrobial prescribing in only two episodes (2.7% of episodes where a sputum was collected).

Sputum analysis is non-invasive, relatively cheap, potentially influences patient management and allows epidemiological surveillance of CAP pathogens and associated antimicrobial susceptibility. However limitations include inherent poor specificity, and the difficulty in detecting pathogens such as *M. pneumoniae*, *Legionella* species and *Chlamydophila* species. Given the low rate of influence of sputum diagnostics, it could be argued that sputum collection be avoided in mild to moderate CAP unless there is clinical suspicion of resistant or unusual pathogens (e.g., *S. aureus*, *P. aeruginosa*, *Mycobacteria* species, *Nocardia* species, *Acinetobacter baumannii*, *Burkholderia pseudomallei*), or failure to respond to therapy.

Only 2.7% of patients underwent testing for respiratory viruses (2.9% for moderate to severe CAP) and this accounts for the low rate of respiratory virus identification (0.5%). Respiratory viruses are becoming increasingly recognised as causes of CAP, and identification allows therapeutic intervention, accurate implementation of infection control practices, while also informing vaccination and public health policy and providing valuable supportive evidence for vaccination to patients and staff.20,21 Possible explanations for low testing rates include perceived lack of a therapeutic intervention, moderate influenza activity during the study period and because of a perceived delay in receipt of results due to specimen referral to an external laboratory.22 Given the recent pandemic of H1N1 influenza A, an increase in diagnostic testing for influenza pneumonia may be expected. Additionally, it has

### Table 1 Causative pathogens in CAP and microbiological identification techniques

| Pathogen                        | Total episodes, n (%) | Microbiological method |
|---------------------------------|-----------------------|------------------------|
| *Streptococcus pneumoniae*      | 10 (5.4)              | 8 × sputum m/c, 2 × UAT, 1 × BC |
| *Mycoplasma pneumoniae*         | 4 (2.2)               | 4 × serology           |
| *Haemophilus influenzae*        | 3 (1.6)               | 3 × sputum m/c         |
| *Moraxella catarrhalis*         | 2 (1.1)               | 2 × sputum m/c         |
| *MSSA*                          | 2 (1.1)               | 1 × BC, 1 × sputum m/c |
| *MRSA*                          | 1 (0.5)               | 1 × BC                 |
| *Parainfluenza*                 | 1 (0.5)               | 1 × resp PCR           |
| *Escherichia coli*              | 1 (0.5)               | 1 × BC                 |
| *Chlamyphilia sp.*              | 1 (0.5)               | 1 × serology           |
| *Legionella*                    | 0 (0.0)               | NA                     |
| Episodes with pathogen*         | 24 (13.0)             |                        |

1 One patient had *S. pneumoniae* detected by both sputum culture and urinary antigen.
2 One patient had both *H. influenzae* and *M. catarrhalis* isolated from sputum.
3 BC, blood cultures; m/c, microscopy and culture; MRSA, methicillin resistant *Staphylococcus aureus*; MSSA, methicillin sensitive *S. aureus*; NA, not applicable; resp PCR, respiratory virus polymerase chain reaction; UAT, pneumococcal or legionella urinary antigen test.
only been relatively recently that multiplex respiratory virus nucleic acid amplification tests of flocculated swabs of the nasopharynx have become readily available.23

The absolute yield of respiratory virus PCR was limited in this study due to low utilisation. Published studies have demonstrated a yield of 12–13% for respiratory virus PCR in CAP, which is relatively high for CAP investigations.21,24 Thus, this test should be recommended for all inpatients with moderate to severe CAP, or those with clinical or epidemiological features suggestive of a viral aetiology, particularly during seasonal peaks. An important caveat is that although molecular techniques for respiratory viruses have been reported to increase microbiological diagnostic sensitivity in CAP, the significance of detecting pathogens such as coronaviruses and rhinoviruses remains uncertain.20 Additionally, testing in smaller centres may be associated with significant costs and time delays due to specimen referral.

Of those with moderate to severe CAP, 20.2% had LUAT and 15.4% had PUAT performed. Urine is more commonly available for testing than sputum, and with a rapid turn around time and greater sensitivity and specificity than sputum, urinary antigen studies should be the preferred investigation option for those with moderate to severe CAP. Disadvantages include lack of antimicrobial susceptibility information, cost and the limited serotypes detected by LUAT (only L. pneumophila serotype 1 is reliably detected, which accounts for 80–95% of community acquired legionella).25,26 Additionally, the yield of PUAT and LUAT was low at 5.7% and 0%, respectively. Nevertheless, a positive result allows antibiotic rationalisation, may limit further diagnostic testing and facilitates early detection of Legionella outbreaks.4

In this study, paired acute and convalescent serological evaluation was rarely performed (in only 5/75 instances where acute serology was performed was convalescent serology performed). Aside from M. pneumoniae IgM testing, isolated evaluation of acute serological samples is rarely helpful and can be misleading. A more rational approach would be to store acute samples and await a convalescent sample before testing both in parallel. Yield of serological testing was highest for M. pneumoniae, however the specificity of a single antibody titre ≥160 (the definition used in this study, as recommended by the manufacturer), has been criticised.26

Serological tests remain vital for pathogens where identification via other means is limited (e.g., M. pneumoniae, Chlamydia species and C. burnetti), however molecular techniques have improved diagnostic accuracy and timing.15,21 Local availability and cost restrict the widespread implementation of these techniques.12 Given limitations of serological studies, little influence on antimicrobial prescribing would be expected, and is supported by this study where antimicrobial prescribing appeared to be influenced by only one of 75 serological tests performed.

To summarise the above controversies, Table 2 provides recommendations for diagnostic microbiology in CAP. These recommendations have been adapted from local and international guidelines, and incorporate findings from our study.3,4,12,17,19,27 To facilitate implementation, and ensure sustained utilisation, we propose development of local clinical pathways. Clinical pathways improve adherence to treatment guidelines, although assessment of impact on investigation utilisation (other than as part of ‘bundles of care’) is limited.28,29

Our study had a number of important limitations. As a single centre retrospective audit, the findings need to be cautiously applied to other population groups. Local guidelines and practices may have influenced utility of diagnostic investigations and antimicrobial prescribing which also limits generalisation. Low overall numbers and limited diagnostic utility, especially with respiratory virus PCR, may compromise the findings. The PSI is known to have a number of limitations, and thus by using the PSI in this study, correlates of severity are inherently restricted. Sputum was not routinely cultured for Legionella sp., serology for non-pneumophila Legionella species was not performed (which have been shown to be important contributors to CAP in Australia) and evaluation for uncommon CAP pathogens was not assessed (e.g., Mycobacterium tuberculosis, fungal pathogens, Nocardia species, Bordetella pertussis).30 Strict criteria applied to sputum analysis may have underestimated diagnostic utility and hence the influence on antibiotic management. No cost-benefit analysis of investigations was performed.

This study demonstrates that the microbiology of CAP in a regional setting mirrors that of CAP in other temperate settings.1 This study also demonstrates that in routine clinical practice, microbiological investigations, particularly respiratory virus PCR and urinary antigens, are under-utilised, especially in admitted patients with moderate to severe CAP. While diagnostic yield for blood cultures is low, positive results strongly influence management and provide important prognostic information. Other investigations such as serological testing and sputum studies appear to have limited impact on patient management, and due to their poor specificity, could be reserved for specific clinical situations. Increasing clinician awareness of modern microbiological techniques in the assessment of patients with CAP, and incorporation into CAP clinical pathways, may lead to improved and efficient utilisation of these resources.28,29

### Table 2: Recommended microbiological investigations for CAP according to severity

| Investigation | Outpatient | Inpatient (non-severe) | Inpatient (severe) |
|---------------|------------|------------------------|--------------------|
| Influenza PCR | O          | R¹                    | R¹                 |
| Respiratory virus PCR | NR, O² | O²                    | R²                 |
| Blood cultures | NR         | R                     | R                  |
| Legionella UAT | NR         | O                     | R                  |
| Pneumococcal UAT¹ | NR | O                     | R                  |
| Sputum m/c ¹ | NR        | O                     | O                  |
| Serological studies¹ | NR | O                     | O                  |
| Other investigations* | NR | O                     | O                  |

¹Severe CAP = all patients admitted to either HDU or ICU. Non-severe CAP = all other admitted patients.
²Respiratory virus PCR usually includes influenza A/B. Respiratory virus molecular studies are particularly encouraged during seasonal outbreaks.
³Not for use in children.
⁴Collect prior to antibiotic administration.
⁵Includes Mycoplasma sp., Chlamydia sp., Legionella sp., influenza, Q fever and other rarer causes of CAP. Epidemiological risk factors may prompt serological evaluation. Blood for serology should at the very least be stored for all those with severe CAP, and a convalescent sample collected on an as needed basis.
⁶Includes bronchoalveolar lavage, investigations for Mycobacterium tuberculosis, and molecular techniques for Mycoplasma sp., Legionella sp., Chlamydia sp., Pneumocystis jiroveci and fungal pathogens.
⁷NR, generally not recommended; O, optional; PCR, polymerase chain reaction; R, generally recommended; UAT, urinary antigen test; m/c, microscopy and culture.
Acknowledgements: Associate Professor James Hurley (Ballarat Health Services) for his critical review of the manuscript.

Conflicts of interest and sources of funding: The authors state that there are no conflicts of interest to disclose.

Address for correspondence: Dr C. Jeremiah, The Northern Hospital, 185 Cooper Street, Epping, Vic 3076, Australia. E-mail: cameron.jeremiah@nh.org.au

References

1. Charles PG, Whitby M, Fuller AJ, et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46: 1513–21.
2. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47: 375–84.
3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27–72.
4. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3): iii1–55.
5. Lutfiyya MN, Henley E, Chang LF, Rayburn SW. Diagnosis and treatment of community-acquired pneumonia. Ann Fam Physician 2006; 73: 442–50.
6. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243–50.
7. Therapeutic Guidelines Limited. Therapeutic Guidelines: Antibiotic. 13th ed. Melbourne: Therapeutic Guidelines Limited, 2006.
8. Druce J, Tran T, Kelly H, et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002–2003. J Med Viral 2005; 75: 122–9.
9. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest 1998; 114: 1588–93.
10. Hohenthal U, Vainionpaa R, Meurman O, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis 2008; 40: 131–8.
11. Howard LS, Sillis M, Pastore MC, Kamath AV, Harrison BD. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 2005; 50: 107–13.
12. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 (Suppl 4): S296–304.
13. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991–2001.
14. Ewig S, Bauer T, Eiser C, Marklein G, Kubini R, Lutheritz B. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center. Respir Med 1996; 63: 164–9.
15. Woodhead MA, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respir Med 1991; 85: 313–7.
16. Lim I, Shaw DR, Stanley DP, Lumb R, McNann G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 1989; 151: 87–91.
17. Charles PG, Johnson PD, Grayson ML. Comordums in community-acquired pneumonia. Med J Aust 2006; 185: 131–2.
18. Charles PG, Grayson ML. Point-of-care tests for lower respiratory tract infections. Med J Aust 2007; 187: 36–9.
19. Charles PG. Early diagnosis of lower respiratory tract infections (point-of care tests). Curr Opin Pulm Med 2008; 14: 176–82.
20. Templeton KE, Scheltinga SA, Van den Eeden WC, Graffelman AW, Van den Broek PJ, Claas EC. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41: 345–51.
21. Johansson N, Kalim M, Tiveljung-Lindell A, Giske CG, Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50: 202–9.
22. Kaczmarek M, Owen R, Barr IG. Annual report of the National Influenza Surveillance Scheme, 2008. Commun Dis Intell 2010; 34: 8–22.
23. Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21: 716–47.
24. Dierdien BM, Van Der Eerden MM, Vlaspolder F, Boersma WG, Klaaymans JA, Peeters MF. Detection of respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community-acquired pneumonia. Scand J Infect Dis 2009; 41: 45–50.
25. Steele TW. Legionnaires’ disease in South Australia, 1979–1988. Med J Aust 1989; 151: 322; 5–6, 8.
26. Barker CE, Sillis M, Wreghitt TG. Evaluation of Serodia Myco II particle agglutination test for detecting Mycoplasma pneumoniae antibody: comparison with nu-capture ELISA and indirect immunofluorescence. J Clin Pathol 1990; 43: 163–5.
27. Therapeutic Guidelines Limited. Therapeutic Guidelines: Antibiotic. 14th ed. Melbourne: Therapeutic Guidelines Limited, 2010.
28. Wolff AM, Taylor SA, McCabe JF. Using checklists and reminders in clinical pathways to improve hospital inpatient care. Med J Aust 2004; 181: 428–31.
29. Hauck LD, Adler LM, Mulla ZD. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol 2004; 14: 669–75.
30. Korman TM, Fuller A, Ibrahim J, Kaye D, Bergin P, Fatal Legionella longbeachae infection following heart transplantation. Eur J Clin Microbiol Infect Dis 1998; 17: 53–5.